In particular, APR-246 (PRIMA-1met), the methylated analogue of PRIMA-1 (p53-reactivation and induction of massive apoptosis-1), is the first mut-p53 reactivating compound to enter clinical trials in patients with hematologic and solid malignancies, such as gastric, bladder and NSCLC, that bear p53 mutations. This evidence concerns the gene TP53 and non-small cell lung carcinoma.